Cargando…

Hyperphosphatemia: The hidden killer in chronic kidney disease

Hyperphosphatemia is a major cause of morbidity and mortality in patients with chronic kidney disease. The association between hyperphosphatemia and increased risk of death from cardiovascular disease/vascular calcification has been well established for a long time. This review explores the new aspe...

Descripción completa

Detalles Bibliográficos
Autor principal:	Askar, Akram M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Saudi Medical Journal 2015
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362181/ https://www.ncbi.nlm.nih.gov/pubmed/25629999 http://dx.doi.org/10.15537/smj.2015.1.9843

Ejemplares similares

Hyperphosphatemia Management in Patients with Chronic Kidney Disease
por: Shaman, Ahmed M., et al.
Publicado: (2016)

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Understudied Hyperphosphatemia (Chronic Kidney Disease) Treatment Targets and New Biological Approaches
por: Anand, Ajeeta, et al.
Publicado: (2023)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Targeting Gastrointestinal Transport Proteins to Control Hyperphosphatemia in Chronic Kidney Disease
por: Fouque, Denis, et al.
Publicado: (2018)

Phosphate Absorption and Hyperphosphatemia Management in Kidney Disease: A Physiology-Based Review
por: Fishbane, Steven N., et al.
Publicado: (2021)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Effect of lanthanum carbonate and calcium acetate in the treatment of hyperphosphatemia in patients of chronic kidney disease
por: Scaria, P. Thomas, et al.
Publicado: (2009)

Targeting NaPi-IIb for Hyperphosphatemia in Chronic Kidney Disease Patients - The Dead End?
por: Apetrii, Mugurel, et al.
Publicado: (2021)

Comparison of the association intensity of creatinine and cystatin C with hyperphosphatemia and hyperparathyroidism in patients with chronic kidney disease
por: Min, Byungju, et al.
Publicado: (2023)

Paratuberculosis: The Hidden Killer of Small Ruminants
por: Idris, Sanaa M., et al.
Publicado: (2021)

Elevated Cardiac Markers in Chronic Kidney Disease as a Consequence of Hyperphosphatemia-Induced Cardiac Myocyte Injury
por: Wang, Shu, et al.
Publicado: (2014)

Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis
por: Zhao, Lijuan, et al.
Publicado: (2021)

Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease
por: Tani, Takashi, et al.
Publicado: (2017)

Severe Hyperphosphatemia in a Patient with Mild Acute Kidney Injury
por: Pham, Phuong Chi, et al.
Publicado: (2021)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma–to strengthen the case toward renal replacement therapy?
por: Latus, Joerg, et al.
Publicado: (2013)

Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease
por: Gao, Ying, et al.
Publicado: (2018)

Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective
por: Reddy, Yogesh NV, et al.
Publicado: (2014)

Association between serum fibroblast growth factor‐23 concentration and development of hyperphosphatemia in normophosphatemic dogs with chronic kidney disease
por: Miyakawa, Hirosumi, et al.
Publicado: (2021)

Ferric citrate for the treatment of hyperphosphatemia and anemia in patients with chronic kidney disease: a meta-analysis of randomized clinical trials
por: Li, Li, et al.
Publicado: (2022)

Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
por: Bolignano, Davide, et al.
Publicado: (2022)

The Impact of Medical Nutrition Intervention on the Management of Hyperphosphatemia in Hemodialysis Patients with Stage 5 Chronic Kidney Disease: A Case Series
por: Moroșan, Elena, et al.
Publicado: (2023)

Npt2a as a target for treating hyperphosphatemia
por: Thomas, Linto, et al.
Publicado: (2022)

Hyperphosphatemia and risks of acute kidney injury, end-stage renal disease, and mortality in hospitalized patients
por: Moon, Hongran, et al.
Publicado: (2019)

Incremental cost-utility of sevelamer relative to calcium carbonate for treatment of hyperphosphatemia among pre-dialysis chronic kidney disease patients
por: Nguyen, Hai V., et al.
Publicado: (2016)

Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease
por: Zhang, Yue-yue, et al.
Publicado: (2018)

Management of hyperphosphatemia in patients with end-stage renal disease: focus on lanthanum carbonate
por: Persy, Veerle P, et al.
Publicado: (2009)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Effect of Intradialytic Exercise on Hyperphosphatemia and Malnutrition
por: Salhab, Nada, et al.
Publicado: (2019)

Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
por: Vallée, Michel, et al.
Publicado: (2021)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Hyperphosphatemia is associated with anemia in adults without chronic kidney disease: results from the National Health and Nutrition Examination Survey (NHANES): 2005–2010
por: Wojcicki, Janet M
Publicado: (2013)

Hidden Acid Retention with Normal Serum Bicarbonate Level in Chronic Kidney Disease
por: Koh, Eun Sil
Publicado: (2023)

Protein-Bound Uremic Toxins Lowering Effect of Sevelamer in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized Controlled Trial
por: Takkavatakarn, Kullaya, et al.
Publicado: (2021)

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
por: Shin, Sooyoung, et al.
Publicado: (2014)

Efficacy and Safety of Sevelamer Carbonate in Chinese Nondialysis Chronic Kidney Disease Patients with Hyperphosphatemia: A Randomized, Double-Blind, Parallel-Group Study
por: Chen, Wei, et al.
Publicado: (2022)

Hyperphosphatemia is associated with high mortality in severe burns
por: Kuo, George, et al.
Publicado: (2018)

Meta-analysis of the efficacy and safety of sevelamer as hyperphosphatemia therapy for hemodialysis patients
por: Zeng, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k8pfs0pqksgpfpi023h44766uo